Coherence Neuro placed its investigational cancer implant in three patients during brain tumor resection surgery at Royal Melbourne Hospital, marking the company's first in-human move. Led by Dr. Andrew Morokoff, who also performed Synchron's first implant, Coherence's trial will evaluate the cortical probe's ability to map and stimulate brain activity intraoperatively with high spatial resolution. Each placement lasted roughly 30 minutes. The data will be used for SOMA-1, Coherence's second-generation implant designed to sense and stimulate the tumor microenvironment as a longer-term therapeutic approach to brain cancer.